Novartis appoint Haseeb Ahmad as MD, UK and Ireland

Ahmad has also been appointed Country President UK and will be a member of the Novartis European Executive Committee

Novartis Pharmaceuticals UK has announced the appointment of Haseeb Ahmad as Managing Director UK and Ireland for the Pharmaceuticals business and Country President UK.

Ahmad said:

“I have greatly admired Novartis – it has a rich history and heritage, life changing medicines and an exciting pipeline.”

He joins Novartis from Merck Sharp and Dohme, where he was Managing Director for MSD Greece, Cyprus and Malta.

Ahmed brings almost 20 years of experience in the industry at a multi-country and global level, including more than 13 years based in the UK.

“The UK is very important as a market,” said Ahmad. “It is at the forefront of healthcare reform and through partnership with the NHS.”

In the UK, Novartis develops, manufactures and markets medicines, devices and diagnostic tests to improve patient outcomes.

You may also like

Regulatory

Novartis obtains FDA approval for CML drug, Scemblix

The TKI's approval is an important step forward for oncology patients with newly diagnosed chronic myeloid leukaemia, and was based on the results of the Phase III ASC4FIRST trial
Pharmaceutical

Pharma giants Roche and Novartis top worldwide reputation poll

The report examined the reputations of the 34 biggest pharmaceutical companies globally, including GSK, Novartis, Pfizer, Moderna and Johnson & Johnson
Manufacturing

Novartis opens facility for innovative cell and gene therapies in Switzerland

New building in Stein also hosts the production of difficult-to-manufacture solid dosage forms
Finance

Lonza to buy sterile drug product fill-finish facility from Novartis

Swiss CDMO bids to keep management and operations teams and manufacture for Novartis at the site in Stein
Regulatory

Novartis starts voluntary recall after peanut contamination scare

Three lots of Promacta 12.5 mg for oral suspension to the consumer level have been recalled due to cross-contamination risk
Research & Development

Blackstone and Novartis: Joint venture targets cardiovascular disease

Anthos Therapeutics enters the market with US$250 million backing from Blackstone and an anti-thrombotic licensed from Novartis
Ingredients

Therapeutics: anticancer agent: alpelisib

Phosphoinositide 3-kinase enzymes are a group of intracellular signal transducers that phosphorylate the 3-hydroxyl group of phosphatidylinositol
Subscribe now